A study led by Yelena Janjigian, MD, has analyzed the landscape of late-stage gastric cancer (GC) using data from the KEYNOTE-059, -061, and -062 studies in patients of Western and Asian origin. Data was compared with early-stage GC data from The Cancer Genome Atlas (TCGA). Bulk DNA taken from pretreatment tumor samples was analyzed using whole-exome sequencing (WES; KEYNOTE-059, KEYNOTE-061) and FoundationOneCDx (KEYNOTE-062) to determine TCGA-defined molecular subtypes (Epstein-Barr virus-positive, microsatellite instability-high ...
Gastric
Advertisement
Pembrolizumab previously received accelerated approval for this indication in 2021 based on interim results from KEYNOTE-811.
The safety profile of the combination was consistent with known profiles, and no new safety findings were observed.
Dr. Cytryn shares insights on the implications of recent data from the DESTINY-Gastric04 and MATTERHORN trials.
Dr. Albiges shares her thoughts on the FDA approval of subcutaneous nivo in gastric cancer and how it will impact practice.
Dr. Cytryn summarizes a trial in progress investigating a novel immunotherapy combination for gastroesophageal adenocarcinoma
Patients with locally advanced GC who achieved pCR after NAC had significantly better survival outcomes.
The panel discusses considerations around treating peritoneal gastric cancer, including the role of HIPEC.
In part three of their discussion, the panel explores the role of ADCs in treating gastric and esophageal cancers.
The panelists discuss the impact of biomarkers on personalized gastric cancer care, including ctDNA, claudin 18.2, and PD-L1.
An expert panel of GI oncologists debates recent advancements in biomarker-driven strategies for GI cancer care.
Advertisement
Roundtables
The panel discusses considerations around treating peritoneal gastric cancer, including the role of HIPEC.
In part three of their discussion, the panel explores the role of ADCs in treating gastric and esophageal cancers.
The panelists discuss the impact of biomarkers on personalized gastric cancer care, including ctDNA, claudin 18.2, and PD-L1.
An expert panel of GI oncologists debates recent advancements in biomarker-driven strategies for GI cancer care.
Video Insights
Advertisement
Section Editor
Samuel Cytryn, MDGastrointestinal Medical Oncologist | Memorial Sloan Kettering Cancer Center
Advertisement
Latest GI Oncology News
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.